European Multi-centre open, adaptive, randomised interventional trial on Influenza-Like-Illness (ILI) in Primary Care (PC).
Individually randomised, open clinical trial (in an adaptive design) comparing the clinical and cost effectiveness of oseltamivir with usual care on duration and control of symptoms in patients presenting to primary care with ILI. At least 4500 participants aged one year or older, presenting with ILI in primary care will be recruited over three winter seasons during times of confirmed, high influenza incidence. Patient randomisation will be remote from the treating clinician and stratified by country and age group (1 to ≤11, 12 to ≤65, >65 years of age).
POCT diagnostic sub-study: The predictive values, sensitivity, specificity and added diagnostic performance characteristics of a novel POCT, the IDYLLA Biocartis platform, will be determined in the laboratory using data and samples from recruited participants.
Login as a member to see more information.